Amid the gloom, Birinyi Associates' Cleve Rueckert found what he sees as a bright spot in the stock market. In a note, he says growth is the place to be, based on performance of the S&P's Pure Growth Index versus the S&P Pure Value Index. Here's his list of 15 stocks in the S&P 500 that fit three key growth criteria.
At the risk of offending our gracious hosts here at the Generic Pharmaceutical Association's Silver Anniversary Meeting, I wanted to talk about the seemingly incongruous venue for the event.
Despite the ongoing recession, generic drug makers like Teva Pharmaceutical and Watson Pharmaceutical have been outperforming in the broader market. CEOs William Marth and Paul Bisaro both expect to see further growth.
Cramer makes the call on viewers' favorite stocks.
Fast Money now – the plays you need while the market is still open
Options action on Watson Phamaceuticals indicates that traders think it might be a takeover target, according to one options experts
Cramer ventures a guess as to who's next on the takeover list.
arr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.
Following are the day’s biggest winners and losers. Find out why shares of Delta Airlines and Office Depot popped while Energizer and Altria dropped.
Barr Pharmaceuticals said Wednesday quarterly earnings fell sharply, hurt by costs tied to an acquisition, but its operating profit beat Wall Street estimates as generic drug sales soared
Here's our Fast Money Final Trade. Our guys give you tomorrow's best trades, tonight!